EI
TOVX icon

EAM Investors’s Theriva Biologics TOVX Stock Holding History

EAM Investors’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-56
Closed -$1.11M – 358
2015
Q3 		$1.11M Buy
+56
New +$1.38M 0.18% 249
2014
Q2 		– Sell
-51
Closed -$1.14M – 363
2014
Q1 		$1.14M Buy
+51
New +$1.06M 0.2% 278

Other funds holding TOVX

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BGA
Belmont Global Advisors Dallas, Texas $106M AUM 2.89% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

EAM Investors's TOVX Position: Q4 2015 in Review

EAM Investors sold out of Theriva Biologics (TOVX) in Q4 2015, closing a stake of 56 shares — an estimated $1.11M sold.

EAM Investors first reported a position in TOVX in Q1 2014 and held it in 2 quarters. The position peaked at $1.14M in Q1 2014. 51 funds tracked by Wall St. Rank hold TOVX as of Q4 2015.

  • EAM Investors reported no remaining Theriva Biologics position as of Q4 2015 after selling out during the quarter.
  • EAM Investors sold 56 Theriva Biologics shares in Q4 2015, an estimated $1.11M.
  • EAM Investors first reported a position in Theriva Biologics in Q1 2014 and held it in 2 quarters.
  • EAM Investors's Theriva Biologics position peaked at $1.14M in Q1 2014.
  • 51 funds tracked by Wall St. Rank held Theriva Biologics as of Q4 2015.

Based on EAM Investors's 13F filing for Q4 2015, filed 5 Feb 2016.